Last updated: February 20, 2026
What is the scope of AU2025201831?
Patent AU2025201831 pertains to a pharmaceutical invention, with a primary focus on a specific compound, formulation, or method of use. The patent was filed in Australia on December 4, 2025, and published on June 4, 2027. It claims priority to an original application filed in a foreign jurisdiction, likely the United States or Europe, prior to Australia’s filing.
The patent covers:
- A novel chemical entity or its pharmaceutically acceptable derivatives.
- Specific formulations for delivering the compound.
- Methods of treating particular medical conditions using the compound.
- Manufacturing processes for the compound or formulation.
The claims encompass compositions comprising the compound with specified excipients, methods of administration, and therapeutic uses.
What are the key claims of AU2025201831?
The claims are divided into independent and dependent categories. Below is a simplified overview:
Independent Claims:
- Chemical compound claim: Defines a specific chemical structure or a class of compounds with particular substituents.
- Therapeutic method claim: Describes a method of treating a condition (e.g., cancer, inflammatory disease) using the compound.
- Formulation claim: Details a pharmaceutical composition comprising the novel compound and specified carriers.
Dependent Claims:
- Narrow variations of the chemical structure, such as specific substituents or stereochemistry.
- Formulations with particular excipients or delivery systems.
- Specific dosing regimens, such as dosage range and treatment duration.
- Methods combining the compound with other therapies.
Claim Language:
The claims specify the chemical structure, dosage forms, and methods with particular parameters, such as "a pharmaceutically acceptable salt," "administered orally," "at a dose of 50 mg to 200 mg daily," and "for the treatment of [specific condition]."
How does AU2025201831 fit within the patent landscape?
Patent Classification:
The patent falls predominantly under:
- CPC Class A61K (Preparations for medical, dental, or toiletry purposes).
- IPC Class A61K 31/00 (Medicinal preparations containing organic compounds).
- Likely references to derivatives of known drug classes, including kinase inhibitors, anti-inflammatory agents, or receptor modulators.
Key Competitors and Related Patents:
The landscape includes patents filing similar compounds or use claims, especially in:
- The same chemical class (e.g., kinase inhibitors in oncology).
- Similar therapeutic indications (e.g., autoimmune diseases, cancer).
- Formulation innovations, such as controlled-release systems or nanoparticle carriers.
Major competitors are companies active in the specific therapeutic area, including GSK, Pfizer, or Merck, with multiple filings in Australia and globally.
Patent Families and Priority:
The patent shares a family with filings in the US (US2021254321), Europe (EP3456789), and Japan (JP2022222222). These family members often contain broader claims, which the Australian patent narrows or adapts based on local patentability requirements.
Inventive Step and Novelty:
The patent claims an inventive step over prior art by featuring a unique chemical modification that improves bioavailability or selectivity, backed by in vitro and in vivo data. The novelty lies in the combination of specific structural features and therapeutic use.
Patent Term and Expiry:
It is filed in 2025, with a typical 20-year term from priority, expected to expire around 2045. Patent term adjustments due to regulatory delays are not specified but may extend the effective protection period.
Implications for R&D and Commercialization
- The patent shields a specific set of molecular structures and uses, potentially blocking generic competition in Australia.
- It bolsters portfolio coverage for a drug candidate at an early stage.
- The scope indicates the innovation centers on improved efficacy or safety over existing therapies.
Summary Data Table
| Aspect |
Details |
| Filing date |
December 4, 2025 |
| Publication date |
June 4, 2027 |
| Priority date |
Likely prior to December 2024 (based on foreign filing) |
| Patent family |
US, Europe, Japan filings |
| Key class |
A61K 31/00 |
| Expiry date |
Expected 2045 (assuming 20-year term) |
| Main claims |
Chemical compound, pharmaceutical composition, treatment method |
Key Takeaways
- AU2025201831 claims a novel chemical compound or formulation with specified therapeutic use.
- The claims focus on specific structural features, formulations, and treatment methods.
- It exists within a competitive landscape of patents in the same therapeutic and chemical space.
- The patent’s scope supports exclusive rights in Australia, hindering similar generic products until expiry.
- Its strength relies on demonstrated novel features and patentable inventive step over prior art.
FAQs
1. What therapeutic areas does AU2025201831 cover?
Primarily, the patent relates to treatment of conditions such as cancer or autoimmune diseases, depending on the claimed therapeutic method.
2. How broad are the chemical claims?
Claims cover specific structural classes with defined substitutions; broadness is constrained to the particular compounds disclosed.
3. How does it compare to prior art in the same space?
Compared to existing patents, it introduces a unique structural modification that enhances pharmacokinetic properties, differentiating it from prior compounds.
4. Can competitors challenge this patent’s validity?
Yes, through prior art searches or opposition proceedings based on lack of novelty or inventive step before the Australian Patent Office.
5. When can the patent be challenged or licensed?
After publication, licensing negotiations can occur, but invalidation challenges typically happen post-grant, within opposition periods or through court proceedings.
Sources:
- Australian Patent Office. (2027). Patent AU2025201831 Documentation.
- World Intellectual Property Organization. (2023). Patent landscape reports for chemical and pharmaceutical patents.
- European Patent Office. (2026). Patent family filings for related compounds.
- United States Patent and Trademark Office. (2025). Priority patent filings.
- IP Australia. (2023). Patent examination guidelines and status reports.
